DrugPatentWatch Database Preview
TIBSOVO Drug Profile
When do Tibsovo patents expire, and what generic alternatives are available?
Tibsovo is a drug marketed by Agios Pharms Inc and is included in one NDA. There are three patents protecting this drug.
This drug has sixty patent family members in thirty-one countries.
The generic ingredient in TIBSOVO is ivosidenib. One supplier is listed for this compound. Additional details are available on the ivosidenib profile page.
Summary for TIBSOVO
| International Patents: | 60 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 28 |
| Clinical Trials: | 1 |
| Patent Applications: | 9 |
| Drug Prices: | Drug price information for TIBSOVO |
| DailyMed Link: | TIBSOVO at DailyMed |
Generic Entry Opportunity Date for TIBSOVO
Generic Entry Date for TIBSOVO*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for TIBSOVO
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Cancer Institute (NCI) | Phase 1 |
| Academic and Community Cancer Research United | Phase 1 |
Synonyms for TIBSOVO
| (2S)-1-(4-Cyano-2-pyridinyl)-5-oxo-L-prolyl-2-(2-chlorophenyl)-N-(3,3-difluorocyclobutyl)-N2-(5-fluoro-3-pyridinyl)-glycinamide |
| (2S)-N-[(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl]-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide |
| (S)-N-((S)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide |
| (S)-N-((S)-1-(2-chlorophenyl)-2-(3,3-difluorocyclobutylamino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N- |
| (S)-N-((S)-1-(2-chlorophenyl)-2-(3,3-difluorocyclobutylamino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide |
| 1448347-49-6 |
| A14386 |
| AG-120 |
| ag-120-Ivosidenib |
| AG120 |
| AS-35058 |
| CHEMBL3989958 |
| CS-5122 |
| D11090 |
| EX-A992 |
| Glycinamide, 1-(4-cyano-2-pyridinyl)-5-oxo-L-prolyl-2-(2-chlorophenyl)-N-(3,3-difluorocyclobutyl)-N2-(5-fluoro-3-pyridinyl)-, (2S)- |
| GTPL9217 |
| HY-18767 |
| Ivosidenib |
| Ivosidenib (AG-120) |
| Ivosidenib (USAN/INN) |
| Ivosidenib [INN] |
| Ivosidenib [USAN] |
| Ivosidenib [WHO-DD] |
| MFCD29036964 |
| NCGC00476170-04 |
| NCGC00476170-06 |
| Q2PCN8MAM6 |
| RG120 |
| s8206 |
| SCHEMBL15122512 |
| UNII-Q2PCN8MAM6 |
| ZINC205136523 |
US Patents and Regulatory Information for TIBSOVO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Agios Pharms Inc | TIBSOVO | ivosidenib | TABLET;ORAL | 211192-001 | Jul 20, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Agios Pharms Inc | TIBSOVO | ivosidenib | TABLET;ORAL | 211192-001 | Jul 20, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Agios Pharms Inc | TIBSOVO | ivosidenib | TABLET;ORAL | 211192-001 | Jul 20, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Agios Pharms Inc | TIBSOVO | ivosidenib | TABLET;ORAL | 211192-001 | Jul 20, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for TIBSOVO
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| China | 106496090 | Start Trial |
| Philippines | 12017501419 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2013107291 | Start Trial |
| Singapore | 11201404190P | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
